Literature DB >> 20219488

Trilostane in dogs.

Ian K Ramsey1.   

Abstract

Over the last 10 years, trilostane, a competitive inhibitor of steroid synthesis, is being widely used for the treatment of canine hyperadrenocorticism. Trilostane causes a significant but reversible decrease in cortisol production and a concomitant improvement in clinical signs in most dogs with this common condition. Side effects, though infrequent, can be serious: dogs treated with this drug require regular monitoring. This review summarizes current knowledge of the use of this drug with particular emphasis on its efficacy, safety, adverse reactions, and effects on endocrine parameters. Brief mention is made of its other uses in dogs and other species. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219488     DOI: 10.1016/j.cvsm.2009.10.008

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  13 in total

Review 1.  Update on the use of trilostane in dogs.

Authors:  Julie Lemetayer; Shauna Blois
Journal:  Can Vet J       Date:  2018-04       Impact factor: 1.008

2.  Long-term outcome of myotonia associated with hyperadrenocorticism in 2 dogs.

Authors:  Noriyuki Nagata; Masashi Yuki
Journal:  Can Vet J       Date:  2015-09       Impact factor: 1.008

3.  Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.

Authors:  C M Bonadio; E C Feldman; T A Cohen; P H Kass
Journal:  J Vet Intern Med       Date:  2014-05-26       Impact factor: 3.333

4.  New Insights in the Functional Zonation of the Canine Adrenal Cortex.

Authors:  K Sanders; J A Mol; H S Kooistra; A Slob; S Galac
Journal:  J Vet Intern Med       Date:  2016-04-25       Impact factor: 3.333

5.  Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Rion Uchiyama; Hidekazu Koyama
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

6.  Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.

Authors:  L Macfarlane; T Parkin; I Ramsey
Journal:  Vet Rec       Date:  2016-11-01       Impact factor: 2.695

7.  Clinical Relationship between Cholestatic Disease and Pituitary-Dependent Hyperadrenocorticism in Dogs: A Retrospective Case Series.

Authors:  K-H Kim; S-M Han; K-O Jeon; H-T Kim; Q Li; M-O Ryu; W-J Song; S-C Park; H-Y Youn
Journal:  J Vet Intern Med       Date:  2017-01-08       Impact factor: 3.333

8.  Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.

Authors:  N Nagata; K Kojima; M Yuki
Journal:  J Vet Intern Med       Date:  2016-12-01       Impact factor: 3.333

9.  Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Yumi Nakamura; Hidekazu Koyama
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

10.  ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.

Authors:  Daniel K Langlois; Michele C Fritz; William D Schall; N Bari Olivier; Rebecca C Smedley; Paul G Pearson; Marc B Bailie; Stephen W Hunt
Journal:  BMC Endocr Disord       Date:  2018-05-02       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.